Primary Immunodeficiency Disease Clinical Trial
Official title:
Clinical and Laboratory Online Patient- and Research Database for Primary Immunodeficiencies in Switzerland
Verified date | May 2016 |
Source | University of Zurich |
Contact | n/a |
Is FDA regulated | No |
Health authority | Switzerland: Ethikkommission |
Study type | Observational |
A Swiss national, multi-centre, online patient and research database will be created, using the existing ESID database server system. This database contains disease-specific data from patients with primary (inborn) immunodeficiency diseases (PID).
Status | Enrolling by invitation |
Enrollment | 800 |
Est. completion date | |
Est. primary completion date | December 2018 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Primary Immunodeficiency Disease (PID) Exclusion Criteria: |
Observational Model: Cohort
Country | Name | City | State |
---|---|---|---|
Switzerland | University Hospital Basel | Basel | |
Switzerland | University Hospital Bern | Bern | |
Switzerland | University Children's Hospital Geneva | Geneva | |
Switzerland | University Hospital Lausanne | Lausanne | |
Switzerland | Children's Hospital of Eastern Switzerland and Cantonal Hospital | St. Gallen | |
Switzerland | University Children's Hospital Zurich | Zurich |
Lead Sponsor | Collaborator |
---|---|
University of Zurich | Cantonal Hospital of St. Gallen, University Hospital, Geneva, University of Basel, University of Bern, University of Lausanne |
Switzerland,
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03677557 -
Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment
|
Phase 4 | |
Completed |
NCT02810444 -
Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID
|
Phase 3 | |
Recruiting |
NCT04944979 -
Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)
|
Phase 3 | |
Completed |
NCT02627300 -
Study of Octanorm Subcutaneous IG in Patients With Primary Immunodeficiency Diseases Who Have Completed the SCGAM-01 Trial
|
Phase 3 | |
Not yet recruiting |
NCT03252548 -
Pediatric Primary Immunodeficiency Disease (PID) in China
|
N/A | |
Completed |
NCT03961009 -
Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients
|
Phase 3 | |
Completed |
NCT04842643 -
An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease
|
Phase 3 | |
Not yet recruiting |
NCT06089122 -
Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG
|
Phase 3 | |
Not yet recruiting |
NCT06150833 -
Efficacy and Safety and Pharmacokinetics of Boya IVIG
|
Phase 3 |